Abstract
Malignant gliomas are the most common primary brain tumors. Despite efforts to find effective treatments, these tumors remain incurable. The failure of malignant gliomas to respond to conventional cancer therapies may reflect the unique biology of these tumors, underscoring the need for new approaches in their investigation. Recently, progress has been made in characterization of the molecular pathogenesis of glioblastoma using a developmental neurobiological perspective, by exploring the role of signaling pathways that control the differentiation of neural stem cells along the glial lineage. The transcription factor STAT3, which has an established function in neural stem cell and astrocyte development, has been found to play dual tumor suppressive and oncogenic roles in glial malignancy depending on the mutational profile of the tumor. These findings establish a novel developmental paradigm in the study of glioblastoma pathogenesis and provide the rationale for patient-tailored therapy in the treatment of this devastating disease.
Current Molecular Medicine
Title: STAT3 Regulation of Glioblastoma Pathogenesis
Volume: 9 Issue: 5
Author(s): Nuria de la Iglesia, Sidharth V. Puram and Azad Bonni
Affiliation:
Abstract: Malignant gliomas are the most common primary brain tumors. Despite efforts to find effective treatments, these tumors remain incurable. The failure of malignant gliomas to respond to conventional cancer therapies may reflect the unique biology of these tumors, underscoring the need for new approaches in their investigation. Recently, progress has been made in characterization of the molecular pathogenesis of glioblastoma using a developmental neurobiological perspective, by exploring the role of signaling pathways that control the differentiation of neural stem cells along the glial lineage. The transcription factor STAT3, which has an established function in neural stem cell and astrocyte development, has been found to play dual tumor suppressive and oncogenic roles in glial malignancy depending on the mutational profile of the tumor. These findings establish a novel developmental paradigm in the study of glioblastoma pathogenesis and provide the rationale for patient-tailored therapy in the treatment of this devastating disease.
Export Options
About this article
Cite this article as:
la Iglesia de Nuria, Puram V. Sidharth and Bonni Azad, STAT3 Regulation of Glioblastoma Pathogenesis, Current Molecular Medicine 2009; 9 (5) . https://dx.doi.org/10.2174/156652409788488739
DOI https://dx.doi.org/10.2174/156652409788488739 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma
Current Cancer Therapy Reviews Imaging Tumor Metastases with Molecular Probes
Current Pharmaceutical Design Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging
Mini-Reviews in Medicinal Chemistry Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Current Pharmaceutical Design Epidermal Growth Factor Receptors: A Functional Perspective
Current Radiopharmaceuticals Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug
Current Pharmaceutical Design Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Posttranslational Regulation of O6-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers
Mini-Reviews in Medicinal Chemistry Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease
Current Drug Targets The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
Central Nervous System Agents in Medicinal Chemistry Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Current Medicinal Chemistry Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier
Current Pharmaceutical Design 5-HT3 Receptors
Current Drug Targets - CNS & Neurological Disorders